Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
8,307 people get TEVA articles and Market Currents by email alert.
Get email alerts on TEVA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
Business Wire (May 14, 2013)
-
-
-
-
-
-
-
-
-
-
Business Wire (May 8, 2013)
-
-
To learn more about Seeking Alpha Pro, click here.
-
Teva's CEO Reviews Management Succession (Transcript)Tue, Jan 3, 2012
-
Teva CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 8, 2011 • 1 Comment
-
Teva Pharmaceutical Industries Limited Q2 2010 Earnings Call TranscriptTue, Jul 27, 2010 • 1 Comment
-
Business Wire (May 14, 2013)
-
at CNBC.com (May 9, 2013)
-
at CNBC.com (May 8, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 2, 2013)
-
at CNBC.com (Apr 26, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 23, 2013)
-
at CNBC.com (Apr 11, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Apr 8, 2013)
TEVA vs. ETF Alternatives
Company Description
Teva Pharmaceutical Industries Limited (“Teva”) is a global pharmaceutical company that develops, produces and markets generic drugs in all major therapeutic categories. We are the leading generic drug company in the world – with the leading position in the U.S. (in terms of both value and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, June 18, 2012, 3:23 PM Deutsche Bank says that with a number of upcoming catalysts, it sees an attractive risk/reward profile in Teva (TEVA +0.2%) at current levels. The firm targets a $10 potential upside on the shares, with $3 potential downside. The firm reiterates its Buy rating with a $48 price target. 1 Comment [Healthcare]
- Thursday, June 14, 2012, 8:53 AM Teva's (TEVA +0.4%) Copaxone multiple sclerosis drug performed well vs. a placebo in a Phase III trial that assessed its effectiveness under a new dosage regime of 40mg three times a week rather than the usual 20mg a day schedule. Comment! [Healthcare]
- Monday, June 4, 2012, 1:28 PM Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in 18%-28% of patients, is at the forefront of treatments designed to enable the body's immune-system to kill cancer cells. Other firms in this "revolution in the making" include Merck (MRK), Roche (RHHBY.PK), Teva (TEVA) and GSK (GSK). Comment! [Healthcare]
- Sunday, June 3, 2012, 3:17 AM Drug companies have been presenting trial data at the American Society of Clinical Oncology meeting in Chicago. Showing good results are J&J's (JNJ) Zytiga for prostate cancer, Roche's (RHHBY.PK) T-DM1 and Avastin for breast and ovarian tumors respectively, Teva's (TEVA) Treanda for the immune system, and Bristol Myers' (BMY) BMS-936558 for lung, kidney and skin cancer. 2 Comments [Healthcare, Top Stories]
- Wednesday, May 30, 2012, 12:26 PM Shares of Amarin (AMRN -3.5%) give back much of yesterday's pop on news that Teva Pharmaceutical (TEVA) and Par Pharmaceutical (PRX) lost their bid to sell the generic form of Lovaza. The stock had rocketed higher on perceptions that the court ruling would clear the way for Amarin's AMR101 to launch and price without competition from generic Lovaza products. 2 Comments [Healthcare, On the Move]
- Wednesday, May 30, 2012, 12:07 PM The FDA is warning about a counterfeit version of Teva's (TEVA) ADHD drug Adderall that's currently being sold on websites. The fake pills could pose a health risk, but so far there are no reports of anyone harmed. Comment! [Healthcare]
- Tuesday, May 29, 2012, 6:44 PM A Delaware court has upheld two patents in favor of Pronova's heart drug Lovaza, ruling against Par Pharmaceutical (PRX) and Teva Pharmaceutical (TEVA). The ruling prevents Par and Teva from selling generic versions of Lovaza, which lowers very high levels of triglycerides in the bloodstream. 4 Comments [Healthcare]
- Friday, May 25, 2012, 2:53 PM Despite the recent pullback ahead of management's tempered guidance expectations yesterday, Teva (TEVA -0.2%) shares should still be avoided, says Piper Jaffray. The firm sees limited visibility for the company's generics businesses and lowers its price target to $44 from $45. 3 Comments [Healthcare]
- Thursday, May 24, 2012, 9:05 AM More on Teva (TEVA) 2012 guidance: The EPS of forecast of $5.30-$5.40 is below prior guidance of $5.48-$5.68; revenue prediction of $20B-$21B is below $22B prior. Teva's Europe outlook has been affected by over $1B. If there are businesses that don't fit, "we'll be looking to divest," says CEO Jeremy Levin. 2 Comments [Earnings, Healthcare]
- Thursday, May 24, 2012, 8:58 AM Teva (TEVA) provides 2012 guidance on a conference call to investors, saying it expects EPS of $5.30-$5.40 vs. consensus of $5.59. It forecasts net revenue of $20B-$21B vs. 21.27B. Breakdown: U.S. $10.5B, Europe $5.8B, ROW $4.2B, Copaxone $3.8B. Shares +1.4% premarket. (PR) 2 Comments [Earnings, Healthcare]
- Wednesday, May 9, 2012, 2:22 AM Teva (TEVA): Q1 EPS of $1.47 beats by $0.03. Net revenue of $5.1B (+25% Y/Y) misses by $0.4B. The eurozone's macroeconomic woes resulted in weaker generics sales in that region. Declares a Q1 cash dividend of 1 NIS per share. 9 Comments [Earnings, Healthcare]
- Wednesday, May 9, 2012, 12:05 AM Notable earnings before Wednesday's open: AGU, AOL, ARIA, DF, DTG, ENB, KRO, M, MPEL, TEVA, THI Comment! [Earnings]
- Tuesday, May 8, 2012, 5:30 PM Notable earnings before Wednesday's open: AGU, AOL, ARIA, DF, DTG, ENB, KRO, M, MPEL, TEVA, THI Comment! [Earnings]
- Tuesday, April 10, 2012, 7:18 AM Teva Pharmaceuticals (TEVA) could raise its earnings guidance when it reports next month after landing FDA approval for its narcolepsy-fighting drug Provigil. Israel-based analyst Natali Gotlieb says Teva's prior guidance didn't factor in exclusivity for the drug. Comment! [Global & FX, Healthcare]
- Thursday, April 5, 2012, 1:01 PM Mylan (MYL -2.1%) sues the FDA seeking relief over the 180-day exclusivity granted by the agency to Teva Pharmaceuticals (TEVA +0.4%) over its generic Provigil. Attorneys repping the firm filed the suit at double-speed with the launch of the narcolepsy-fighting drug just crossing the wires less than a week ago. Comment! [Healthcare]
- Thursday, April 5, 2012, 11:15 AM Teva (TEVA +0.65%) yesterday sued Dutch firm Synthon in New York for infringing seven patents as it readies plans to sell a generic version of Teva's blockbuster multiple sclerosis drug Copaxone before the patents expire. Synthon argues that Teva's claims are invalid or unenforceable. 1 Comment [Healthcare]
-
- View all 0 replies
-
- View all 3 replies
-
-
-
Michael Eisenberg
TEVA says that in next 3 years $150 billion of drugs coming off patent. Translation: $130 Bn in healthcare savings from generics. - View all 0 replies
-
Michael Eisenberg
TEVA generics reduce price of drugs by 88%-92%. THAT makes healthcare more affordable than anything Obamacare can do. - View all 0 replies
-
Michael Eisenberg
Yesterday's $2 billion reduction in Greek healthcare budget is opportunity for TEVA cheaper generic pharmaceuticals...interesting - View all 0 replies
-
- View all 2 replies
-
Mercy Jimenez: Agree added today @$43.50 before the FDA announcement. It also has big upside in Asia: http://reut.rs/wUbQdS -
Alex Rasmussen: Thanks Mercy. Part of the global deleveraging has to be government support for generic drug manufacturers. The consumer only benefits.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 1 replies
-
LATEST REPLIES